EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer

Tsai-Yu Lin, Fu-Ling Chang, Shang-Ju Hsieh, Jia-Huei Zheng, Yen-Chen Lu, Ming-Hui Cheng, Keng-Chang Tsai, Wei-Chun HuangFu, Ching-Sheng Hung, Yu-Ching Lee

Translational Oncology · 2026-12 · 74 · 103074

DOI: 10.1016/j.tranon.2026.103074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2026-12. Verfasst von Tsai-Yu Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Taipei Municipal Wan Fang Hospital, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) lacks reliable biomarkers for early detection and remains a highly aggressive disease. Ephrin type-A receptor 2 (EphA2), a receptor tyrosine kinase frequently overexpressed in advanced cancers, undergoes MMP14-mediated cleavage that releases soluble N-terminal fragments. Here, we investigated the diagnostic and functional significance of this fragment in TNBC. Immunohistochemical analysis of clinical specimens revealed elevated EphA2 expression in TNBC tissues, with a trend toward higher levels in tumors of advanced stage and grade. To enable non-invasive detection, we established a dual-epitope sandwich ELISA targeting spatially distinct regions of the EphA2 extracellular domain. The assay showed concentration-dependent detection of recombinant EphA2 (EC₅₀, 48 ng/mL) and detected soluble EphA2 in TNBC cell-conditioned media. Serum analysis showed significantly higher EphA2 levels in TNBC patients compared with healthy controls (median 93.3 vs 25.6 ng/mL). In this exploratory cohort, ROC analysis yielded an AUC of 0.912 (95% CI, 0.862-0.962), with a sensitivity of 95.0% (95% CI, 86.3-98.6%) and a specificity of 78.3% (95% CI, 66.4-86.9%), and higher levels were associated with lymph node metastasis and higher histological grade. Functionally, recombinant EphA2-P328 promoted TNBC-cell migration and induced cell context-dependent changes in EMT-associated markers in vitro. Collectively, these findings support the soluble N-terminal EphA2 fragment as a candidate serum biomarker and an in vitro modulator of TNBC cell migration, warranting validation in larger independent cohorts and further mechanistic investigation.

Schlagwörter

Stichwörter der Autor:innen

Ephrin type-A receptor 2Sandwich ELISASoluble biomarkerTriple-negative breast cancerTumor progression

Autor:innen und Institutionen

  • Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; TMU Research Center of Cancer Translational Medicine, Taipei Medical Universi…
  • Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; Division of Urology, Department of Surgery, Far Eastern Memorial Hospi…
  • Taiwan Autoantibody Biobank Initiative, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • Ph.D. Program in Innovative Medical Technology Research and Development Industry, Taipei Medical University, Taipei, Taiwan.
  • Department of Laboratory Medicine, Lotung PohAi Hospital, Lo-Hsu Medical Foundation, Yilan, Taiwan; Ph.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, T…

Förderung

  • Taipei Municipal Wan Fang Hospital
  • National Science and Technology Council

Zitieren

APA

Lin, T. Y., Chang, F. L., Hsieh, S. J., Zheng, J. H., Lu, Y. C., Cheng, M. H., Tsai, K. C., HuangFu, W. C., Hung, C. S., & Lee, Y. C. (2026). Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer. Translational Oncology, 74, 103074. https://doi.org/10.1016/j.tranon.2026.103074

Vancouver

Lin TY, Chang FL, Hsieh SJ, Zheng JH, Lu YC, Cheng MH, et al. Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer. Translational Oncology. 2026;74:103074. doi:10.1016/j.tranon.2026.103074

BibTeX
@article{Lin2026,
  author = {Lin, Tsai-Yu and Chang, Fu-Ling and Hsieh, Shang-Ju and Zheng, Jia-Huei and Lu, Yen-Chen and Cheng, Ming-Hui and Tsai, Keng-Chang and HuangFu, Wei-Chun and Hung, Ching-Sheng and Lee, Yu-Ching},
  title = {Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer},
  journal = {Translational Oncology},
  year = {2026},
  volume = {74},
  pages = {103074},
  doi = {10.1016/j.tranon.2026.103074}
}
Kostenlos starten →